- Traschütz, Andreas
- Adarmes-Gómez, Astrid
- Anheim, Mathieu
- Baets, Jonathan
- Brais, Bernard
- Gagnon, Cynthia
- Gburek-Augustat, Janina
- Doss, Sarah
- Hanagasi, Hasmet
- Kamm, Christoph
- Klivenyi, Peter
- Klockgether, Thomas
- Klopstock, Thomas
- Minnerop, Martina
- Münchau, Alexander
- Renaud, Mathilde
- Santorelli, Filippo M.
- Schöls, Ludger
- Thieme, Andreas
- Vielhaber, Stefan
- Warrenburg, Bart van de
- Zanni, Ginevra
- Hilgers, Ralf-Dieter
- PREPARE Consortium
- Synofzik, Matthis
© 2023 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., [Objective] The Scale for the Assessment and Rating of Ataxia (SARA) is the most widely applied clinical outcome assessment (COA) for genetic ataxias, but presents metrological and regulatory challenges. To facilitate trial planning, we characterize its responsiveness (including subitem-level relations to ataxia severity and patient-focused outcomes) across a large number of ataxias, and provide first natural history data for several of them., [Methods] Subitem-level correlation and distribution-based analysis of 1,637 SARA assessments in 884 patients with autosomal recessive/early onset ataxia (370 with 2–8 longitudinal assessments) were complemented by linear mixed effects modeling to estimate progression and sample sizes., [Results] Although SARA subitem responsiveness varied between ataxia severities, gait/stance showed a robust granular linear scaling across the broadest range (SARA < 25). Responsiveness was diminished by incomplete subscale use at intermediate or upper levels, nontransitions (“static periods”), and fluctuating decreases/increases. All subitems except nose-finger showed moderate-to-strong correlations to activities of daily living, indicating that metric properties—not content validity—limit SARA responsiveness. SARA captured mild-to-moderate progression in many genotypes (eg, SYNE1-ataxia: 0.55 points/yr, ataxia with oculomotor apraxia type 2: 1.14 points/yr, POLG-ataxia: 1.56 points/yr), but no change in others (autosomal recessive spastic ataxia of Charlevoix-Saguenay, COQ8A-ataxia). Whereas sensitivity to change was optimal in mild ataxia (SARA < 10), it substantially deteriorated in advanced ataxia (SARA > 25; 2.7-fold sample size). Use of a novel rank-optimized SARA without subitems finger-chase and nose-finger reduces sample sizes by 20 to 25%., [Interpretation] This study comprehensively characterizes COA properties and annualized changes of the SARA across and within a large number of ataxias. It suggests specific approaches for optimizing its responsiveness that might facilitate regulatory qualification and trial design. ANN NEUROL 2023;94:470–485, This work was supported via the European Union's Horizon 2020 research and innovation program as part of the innovation project EVIDENCE-RND under the EJP RD COFUND-EJP (No. 825575, to R.-D.H. and M.S.), as part of Solve-RD (No. 779257, to J.B., M.S., and B.P.v.d.W.), by the DFG under the framework of EJP-RD network PROSPAX (No. 441409627; M.S., B.P.v.d.W.), and by the Clinician Scientist program PRECISE.net, funded by the Else Kröner-Fresenius-Stiftung (to A.Tr. and M.S.). The study was further funded by the Federal Ministry of Education and Research, Germany, and through the TreatHSP network (01GM1905 to L.S.). B.P.v.d.W. receives additional research support from ZonMW, Hersenstichting, Gossweiler Foundation, and Radboud University Medical Center. L.S., T.Klop., T.Kloc., G.Z., B.P.v.d.W., and M.S. are members of the European Reference Network for Rare Neurological Diseases–Project ID No. 739510. A.Tr. receives funding from the University of Tübingen, medical faculty, for the Clinician Scientist Program Grant #439-0-0. P.K. receives funding from University of Szeged (Hetényi Géza: 5S330 A202) and Ministry of Innovation and Technology of Hungary, National Research, Development and Innovation Fund (TKP2021-EGA). J.B. is supported by a Senior Clinical Researcher mandate of the Research Fund–Flanders (FWO) under grant agreement number 1805021N, and is a member of the μNEURO Research Center of Excellence of the University of Antwerp. F.M.S. is supported in part by the Italian Ministry of Health (EJP-RD network PROSPAX; Ricerca Finalizzata RF-2016-02361610; RF-2019-12370417; Ricerca Corrente RC 5x1000). Several authors of this publication are members of the European Reference Network for Rare Neuromuscular Diseases and of the European Reference Network for Rare Neurological Diseases., We are grateful to S. Reich for her coordinating support as part of the EOA/PREPARE consortium and to T. Heger for monitoring the datasets of the ARCA registry. Open Access funding enabled and organized by Projekt DEAL., Peer reviewed